AACR14: data from Epic's CTC technology in prostate and lung cancer

In collaboration with the company's academic and pharmaceutical partners, Epic's technology will be featured in two talks and two posters at the 105th Annual Meeting of the American Association for Cancer Research (AACR), April 5-9, 2014 in San Diego.  

Talks

Validation of blood based molecular biomarkers

April 5, 8:30 am - 8:55 am, Room 6A

Howard I. Scher (1), Ryan Dittamore (2), Jorge S. Reis-Filho (1).

(1) Memorial Sloan-Kettering Cancer Center, New York, NY; (2) Epic Sciences, La Jolla, CA

Understanding tumor heterogeneity in PTEN and other biomarkers in prostate cancer using circulating tumor cells

April 5, 4:27 pm - 4:47 pm, Room 25A-C

Elizabeth Punnoose.

Genentech, Inc., South San Francisco, CA 

Posters

(2841) Characterization of ALK fusions in circulating tumor cells (CTCs) of NSCLC

April 7, 1 - 5 pm, Hall A-E, Poster Section 37

David Lu, Rachel Krupa, Natalee Bales, Jessica Louw, Dena Marrinucci, Ryan Dittamore.

Epic Sciences, La Jolla, CA 

(4819) Evaluation of PTEN status in circulating tumor cells (CTCs) and matched tumor tissue from castrate-resistant prostate cancer (CRPC) patients

April 9, 8 am - 12 pm, Hall A-E, Poster Section 1

Elizabeth Punnoose (1), Eric Tucker (2), Edith Szafer-Glusman (1), Jin Zhu (1), Dena Marrinucci (2), Jessica Louw (2), Florence Lee (2), Mikel Kitchen (2), Natalee Bales (2), Lukas Amler (1), Hartmut Koeppen (1), Premal Patel (1), Yibing Yan (1), Ruth Riisnaes (3), Gerhardt Attard (3), Johann de Bono (3).

(1) Genentech, Inc., San Francisco, CA; (2) Epic Sciences, Inc., La Jolla, CA; (3) The Institute of Cancer Research, Sutton, United Kingdom 

For any media inquiries please email [email protected]. Thank you.